New drug shows promise for lung scarring disease in early trial

NCT ID NCT06747923

First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tests an experimental drug called SB17170 in 30 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The goal is to see if the drug can improve lung function compared to a placebo over 12 weeks. Participants will receive either SB17170 or a placebo, and researchers will measure changes in breathing tests and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ajou University Hospital

    NOT_YET_RECRUITING

    Suwon, South Korea

    Contact

  • Chung-Ang University Gwangmyeong Hospital

    RECRUITING

    Gwangmyeong, South Korea

    Contact

  • Myong Ji Hospital

    RECRUITING

    Goyang, South Korea

    Contact

  • Seoul Asan Hospital

    NOT_YET_RECRUITING

    Seoul, South Korea

    Contact

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital

    NOT_YET_RECRUITING

    Seoul, South Korea

    Contact

Conditions

Explore the condition pages connected to this study.